28Jun 2017

CD160 EXPRESSION IN B CHRONIC LYMPHOCYTIC LEUKEMIA (B-CLL.)

  • Assistant professor, Benha University, faculty of medicine.Egypt.
  • Assistant professor of Clinical Pathologyr Ain Shams University, Faculty of Medicine, Egypt. M.B.B.Ch, Msc.
Crossref Cited-by Linking logo

  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

CLL is usually diagnosed through the charachteristic morphology/immunophenotype of the lymphocytes, but some CLL cases remain atypical resulting in uncertain diagnosis. CD160 is a glycosylphosphatidylinositol-Linked receptor found on normal natural killer (NK) and T cells, but not B cells. Its activation protects against apoptosis and increase mean cell viability. The aim of the study is to analyze expression of CD160 in B-CLL and if there is relation with clinical and laboratory parameters. CD 160 expression was assessed using Flow Cytometry, in 60 newly diagnosed CLL patients in addition to 30, matched age and sex, normal subjects who served as a control group. We found that, CD160 was expressed on a greater percentage of B-CLL cells in patients than in control group (p< 0.01) with very high sensitivity (96.7%) and specificity (100%) , so it can represent a useful diagnostic tool in B-CLL cases. There was no significant difference of CD160 expression in various stages in Binet and Rai staging. We demonstrated a significant statistical positive correlation between CD160 and CD20 (p< 0.05) and a highly significant statistical positive correlation between CD160 and CD19 and CD38 (p< 0.01). No significant correlation was found between CD160 and CD23, CD79b, SIgM, FMC7, CD5 and CD10.There was no significant statistical correlation between CD160 and Hemoglobin level(Hb), platelet count(PLT), total leukocytic count(TLC), Absolute and relative lymphocytic count, bone marrow lymphocytes (BML) and Lactate dehydrogenase(LDH). We concluded that; CD160 was expressed on a greater percentage of B-CLL cells in patients than in control group with very high sensitivity and specificity, so it can represent a useful diagnostic tool in B-CLL cases. CD160 expression may be useful prognostic marker in patients with B- CLL.

  1. Rabot M, Elcosta H, Polgar B, Cardine A M, Aguerre-Girr Aliz M, Salvatore V, Bensussan A Le Bouteiller Ph: CD160-activating NK cell effector functions depend on the phosphatidylinositol 3-kinase recruitment. Int Immunol (2007) 19 (4): 401-409.
  2. Abecassis S1,?Giustiniani J,?Meyer N,?Schiavon V,?Ortonne N,?Campillo JA,?Bagot M,?Bensussan A: Identification of a novel CD160+ CD4+ T-lymphocyte subset in the skin: a possible role for CD160 in skin inflammation. J Invest Dermatol. 2007 May;127(5):1161-6.
  3. Reed J: CBcl-2-family proteins and hematologic malignancies: history and future prospect.Blood (2008) ;111(7):3322.
  4. Niedermeier M, Hennessy BT and Knight ZA: Isoform-selective phosphoinositide 3_-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach. Blood (2009);113(22):5549.
  5. Balakrishnan K, Burger JA, Wierda WG and GandhiV: AT-101 induces apoptosis in CLL B cells andovercomes stromal cell-mediated Mcl-1 inductionand drug resistance. Blood (2009) ;113(1):149
  6. Bannerji R, Byrd JC. Update on the biology of chronic lymphocytic leukemia.?Curr Opin Oncol.?2000;12(1):22?29
  7. Liu FT1, Giustiniani J, Farren T, Jia L, Bensussan A, Gribben JG, Agrawal SG: CD160 signaling mediates PI3K-dependent survival and growth signals in chronic lymphocytic leukemia. Blood. 2010 Apr 15;115(15):3079-88.
  8. Jones B., Adams S., Miller G.T., Jesson M.I., Watanabe T., Wallner B.P. Hematopoietic stimulation by a dipeptidyl peptidase inhibitor reveals a novel regulatory mechanism and therapeutic treatment for blood cell deficiencies. Blood (2003) 102: 1641?1648
  9. Binsky I, Haran M, Starlets D, et al. IL-8 secreted in a macrophage migration-inhibitory factor- and CD74-dependent manner regulates B cell chronic lymphocytic leukemia survival.?Proc Natl Acad Sci U S A.?2007;104(33):13408?13413.
  10. Farren TW, Giustinian J, Lui FT, A.?Tsitsikas D, Macey MG, Cavenagh JD, Oakervee HE, Taussig D, Newland AC, Calaminici M, Bensussan A, Jenner M, Gribben J and Agrawal SG. Differential and tumor-specific expression of CD160 in B-cell malignancies. Blood 2011 118:2174-2183
  11. Terri L: Chronic Lymphocytic Leukaemia : prognostic? factors and impact on treatment . Discov.Med(2011) ;11(57):115.
 

[Deena Elshabrawy, Yasmin Elsakhawy and Eman Ibrahim. (2017); CD160 EXPRESSION IN B CHRONIC LYMPHOCYTIC LEUKEMIA (B-CLL.) Int. J. of Adv. Res. 5 (Jun). 2342-2347] (ISSN 2320-5407). www.journalijar.com

Deena A Elshabrawy
assistant Professor, Benha University, Faculty of medicine, Egypt

DOI:

Article DOI: 10.21474/IJAR01/4678      
DOI URL: https://dx.doi.org/10.21474/IJAR01/4678

Download Full Paper

Download PDF No. of Downloads: 33 | No. of Views: 171